Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$44.30
+1.9%		$33.91
$25.36
▼
$44.48
$2.25B1.2904,317 shs340,910 shs
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$79.47
+5.1%		$86.79
$36.53
▼
$97.59
$2.37B1.07574,767 shs496,985 shs
NovoCure Limited stock logo
NVCR
NovoCure
$16.95
-2.5%		$16.36
$9.82
▼
$21.45
$1.97B0.971.73 million shs681,217 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$42.98
+0.4%		$37.58
$25.87
▼
$43.00
$614.53M1.3269,318 shs5.34 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
0.00%+7.03%+24.37%+57.54%+20.71%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
0.00%+2.65%-13.90%+20.85%+107.28%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%+3.42%+3.23%-3.58%+45.56%
Surmodics, Inc. stock logo
SRDX
Surmodics
0.00%0.00%0.00%0.00%+13.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$44.30
+1.9%		$33.91
$25.36
▼
$44.48
$2.25B1.2904,317 shs340,910 shs
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$79.47
+5.1%		$86.79
$36.53
▼
$97.59
$2.37B1.07574,767 shs496,985 shs
NovoCure Limited stock logo
NVCR
NovoCure
$16.95
-2.5%		$16.36
$9.82
▼
$21.45
$1.97B0.971.73 million shs681,217 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$42.98
+0.4%		$37.58
$25.87
▼
$43.00
$614.53M1.3269,318 shs5.34 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
0.00%+7.03%+24.37%+57.54%+20.71%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
0.00%+2.65%-13.90%+20.85%+107.28%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%+3.42%+3.23%-3.58%+45.56%
Surmodics, Inc. stock logo
SRDX
Surmodics
0.00%0.00%0.00%0.00%+13.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
2.82
Moderate Buy$48.509.48% Upside
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
2.78
Moderate Buy$100.2526.15% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.14
Hold$21.2025.07% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SRDX, ESTA, ATRC, and NVCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$92.00
8/7/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$84.00 ➝ $95.00
8/6/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$105.00
8/6/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$96.00 ➝ $103.00
8/6/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$86.00 ➝ $95.00
8/3/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$95.00 ➝ $117.00
7/28/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D+)
7/28/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$55.00 ➝ $50.00
7/28/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$55.00 ➝ $50.00
7/24/2026
NovoCure Limited stock logo
NVCR
NovoCure
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$32.00
7/24/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$569.62M3.96$0.31 per share141.54$10.15 per share4.36
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$211.08M11.22N/AN/A$0.73 per share108.86
NovoCure Limited stock logo
NVCR
NovoCure
$655.35M3.01N/AN/A$2.90 per share5.84
Surmodics, Inc. stock logo
SRDX
Surmodics
$120.80M5.09$0.49 per share87.04$8.33 per share5.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$11.45M$0.21210.9698.44N/A1.85%2.34%1.77%11/4/2026 (Estimated)
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$51.06M-$1.31N/AN/AN/A-15.82%-196.69%-10.73%11/4/2026 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$136.23M-$1.30N/AN/AN/A-21.25%-44.00%-15.85%10/29/2026 (Estimated)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$11.54M-$1.23N/A53.73N/A-14.59%-2.99%-1.99%N/A

Latest SRDX, ESTA, ATRC, and NVCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$0.3368-$0.39-$0.0532-$0.39$65.79 million$67.54 million
7/23/2026Q2 2026
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.0017$0.18+$0.1817$0.18$151.80 million$153.60 million
7/23/2026Q2 2026
NovoCure Limited stock logo
NVCR
NovoCure
-$0.3315-$0.13+$0.2015-$0.13$172.44 million$183.58 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.14
4.22
3.19
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
12.11
3.84
1.91
NovoCure Limited stock logo
NVCR
NovoCure
0.58
2.89
2.70
Surmodics, Inc. stock logo
SRDX
Surmodics
0.27
3.91
3.10

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
72.91%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
4.00%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
9.99%
NovoCure Limited stock logo
NVCR
NovoCure
6.55%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,30050.87 million48.83 millionOptionable
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
1,00429.80 million26.83 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,605116.45 million108.82 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
45014.30 million13.03 millionOptionable

Recent News About These Companies

Endologix Pounces on Surmodics' Thrombectomy System in Strategic Acquisition
May 20, 2026  |  mddionline.comM
Endologix purchases thrombectomy system from Surmodics
May 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/endologix-purchases-thrombectomy-system-surmodics-105146277.html
Endologix Acquires Pounce System from Surmodics
May 19, 2026  |  ocbj.comO
Surmodics Completes Transition to Private Ownership
February 7, 2026  |  newscase.comN
Biocoat Announces Formation of Surmodics Services & Technologies Division Following Merger and Divestiture Transactions
December 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocoat-announces-formation-surmodics-services-170700279.html
SurModics Completes Merger, Ends Credit Agreement
November 19, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/surmodics-completes-merger-ends-credit-agreement?utm_source=marketbeat.com&utm_medium=referral
Surmodics stock rises after FTC indicates no appeal of merger ruling
November 17, 2025  |  za.investing.comhttps://za.investing.com/news/stock-market-news/surmodics-stock-rises-after-ftc-indicates-no-appeal-of-merger-ruling-93CH-3988175
Surmodics’ acquisition will not be appealed by FTC
November 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/surmodics-acquisition-will-not-be-appealed-by-ftc/ar-AA1QB4d6
Surmodics gains as FTC won't appeal denial of GTCR deal injunction
November 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/mergers-and-acquisitions/surmodics-gains-as-ftc-won-t-appeal-denial-of-gtcr-deal-injunction/ar-AA1QBqcF
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
November 17, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251117640716/en/Surmodics-Announces-FTC-Does-Not-Intend-to-Appeal-Denial-of-Injunction-Order-Preventing-Closing-Set-to-Expire-Today/
Barrington Research Downgrades Surmodics (SRDX)
November 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/barrington-research-downgrades-surmodics-srdx/ar-AA1Qu0w4
SurModics Merger with GTCR LLC Clears Legal Hurdle
November 12, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/surmodics-merger-with-gtcr-llc-clears-legal-hurdle?utm_source=marketbeat.com&utm_medium=referral
Surmodics Shares Skyrocket 50% After Court Rejects FTC Request to Block GTCR Acquisition
November 11, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/surmodics-shares-skyrocket-50-after-court-rejects-ftc-request-to-block-gtcr-acquisition/ar-AA1Qe6LM
GTCR can proceed with Surmodics acquisition after court denies FTC’s attempt to block it
November 11, 2025  |  massdevice.comhttps://www.massdevice.com/gtcr-proceed-surmodics-acquisition-ftc-court/
Surmodics surges after court denies injunction to block sale to GTCR
November 11, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/surmodics-surges-after-court-denies-injunction-to-block-sale-to-gtcr/ar-AA1QdXJq
Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge
November 11, 2025  |  benzinga.comhttps://www.benzinga.com/m-a/25/11/48785094/federal-judge-clears-path-for-gtcrs-takeover-of-surmodics-after-ftc-challenge?utm_source=snapi
Surmodics confirms District Court denies request for preliminary injunction
November 11, 2025  |  msn.comhttps://www.msn.com/en-us/general/general/surmodics-confirms-district-court-denies-request-for-preliminary-injunction/ar-AA1QbZH5
US judge rejects FTC's bid to block private equity medical company deal
November 10, 2025  |  reuters.comhttps://www.reuters.com/world/us-judge-rejects-ftcs-bid-block-private-equity-medical-company-deal-2025-11-10/
Surmodics sale to GTCR approved by federal court
November 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/surmodics-sale-to-gtcr-approved-by-federal-court/ar-AA1QaSf7
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
November 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251110939371/en/surmodics-announces-u.s.-district-court-denies-request-for-preliminary-injunction-to-block-proposed-acquisition-by-gtcr/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A wallet with cash, coffee, a sweater, sunglasses, and perfume on a counter beside a stainless steel refrigerator.
Confidence Is Back, But Earnings Show the Consumer Is Being Picky
By Jessica Mitacek | July 21, 2026
Wingstop logo displayed over a basket of chicken wings inside a restaurant dining area.
Is Wingstop's Growth Story Losing Steam?
By Peter Frank | August 10, 2026
A pepperoni pizza in an open Domino's box sits on a stainless steel prep table in a kitchen.
Is Domino's Stock Serving Up a Buying Opportunity?
By Jeffrey Neal Johnson | July 20, 2026
A CAVA-branded bowl of falafel, grains, and vegetables with hummus, olives, and pita on a restaurant table.
CAVA Earnings: The Easiest Comp of the Year Meets a Tough Valuation
By Chris Markoch | August 14, 2026
A steak cooks over an open flame on a restaurant grill, with kitchen equipment visible in the background.
Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
By Dan Schmidt | August 15, 2026
AtriCure stock logo

AtriCure NASDAQ:ATRC

$44.30 +0.81 (+1.86%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$44.33 +0.03 (+0.07%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Establishment Labs stock logo

Establishment Labs NASDAQ:ESTA

$79.47 +3.88 (+5.13%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$79.46 0.00 (-0.01%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$16.95 -0.43 (-2.47%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$17.26 +0.31 (+1.80%)
As of 08/14/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Surmodics stock logo

Surmodics NASDAQ:SRDX

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas